BioSpace News Archive

Biotech Beach

Thermo Fisher Scientific to Showcase Latest Advances in Tumor Mutation Burden at ECP

European Immuno-Oncology Consortium to present update on TMB standardization efforts and clinical research data derived from new Oncomine Tumor Mutation Load Assay workflow

September 6, 2018
·
3 min read
FDA

ITF Pharma Announces FDA Approval Of TIGLUTIK™ (Riluzole) Oral Suspension For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)

TIGLUTIK, the First and Only Easy-to-Swallow Thickened Riluzole Liquid for ALS, will be Commercially Available Mid-October of 2018

September 6, 2018
·
6 min read
Business

BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors

BeiGene’s RAF dimer inhibitor lifirafenib (BGB-283) and SpringWorks Therapeutics’ MEK inhibitor PD-0325901 to be studied in combination

September 6, 2018
·
7 min read
Pharm Country

Data from Merck’s Leading Lung Cancer Research Program with KEYTRUDA® (pembrolizumab) to be Presented at IASLC 19th World Conference on Lung Cancer

Merck today announced that investigational data from the company’s leading lung cancer research program with KEYTRUDA, Merck’s anti-PD-1 therapy, will be presented at the IASLC 19th World Conference on Lung Cancer

September 6, 2018
·
24 min read
Drug Development

Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)

Merrimack Pharmaceuticals, Inc. today announced that it has completed enrollment in its ongoing SHERLOC study, a Phase 2 clinical trial evaluating its lead investigational drug candidate, MM-121, in patients with heregulin positive NSCLC.

September 6, 2018
·
5 min read
Policy

TransEnterix Announces FDA 510(k) Submission for Senhance Ultrasonic Instrument System

Filed 510(k) submission for Senhance Ultrasonic, broadening the potential applicability of Senhance surgery in the U.S.

September 6, 2018
·
3 min read
BioMidwest

Lilly Announces Webcast to Discuss EASD Presentations

Remarks will focus primarily on data from the Phase 2b study of LY3298176, a GIP and GLP-1 dual receptor agonist.

September 6, 2018
·
1 min read
Policy

Protagonist Therapeutics Expands Intellectual Property Portfolio

Three issued U.S. patents add to existing protection for clinical drug candidates derived from Protagonist’s innovative peptide technology platform

September 6, 2018
·
4 min read
Biotech Bay

Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300

Grant supports translational research for hepcidin mimetic PTG-300 for potential treatment of rare blood disorders

September 6, 2018
·
4 min read
Business

Bristol-Myers Squibb to Announce Results for Third Quarter 2018 on October 25

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2018 on Thursday, October 25, 2018. During a conference call at 10:30 a.m. EDT on October 25,

September 6, 2018
·
1 min read